HIV InfectionsPhase 2NCT00004999
Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients
A Phase 2 study testing Lamivudine/Zidovudine, Capravirine and Nelfinavir mesylate in people with HIV Infections, run by Agouron Pharmaceuticals at 53 sites in 4 countries.
Trial summary
The purpose of this study is to look at the effectiveness of giving a new anti-HIV drug (AG1549) plus Viracept (nelfinavir) plus Combivir (a tablet containing zidovudine plus lamivudine) to HIV-infected patients who are not taking anti-HIV drugs. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- HIV Infections
- What is being tested?
- Lamivudine/Zidovudine, Capravirine and Nelfinavir mesylate
- How many people
- 350 participants
- Where
- 53 sitesin 4 countries
- Study dates
- Aug 1999to not given
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients may be eligible if they:
- Are HIV-positive.
- Are at least 18 years old.
- Have a CD4 cell count of more than 50 cells/mm3.
- Have an HIV level of more than 5000 copies/ml.
Who cannot join
- Patients will not be eligible if they:
- Have ever taken any of the following anti-HIV drugs: nonnucleoside reverse transcriptase inhibitors (NNRTIs), AG1549, Viracept, zidovudine, lamivudine, or Combivir. Other anti-HIV drugs are allowed only if taken for no more than 30 days with the last dose taken more than 6 months prior to study entry.
- Have taken an experimental drug within 28 days of study entry.
Trial locations and contacts
53 sites in 4 countries.
53 sites in 4 countries
United States46 sites
IDC Research Initiative
Altamonte Springs, Florida, 32701
Sky Blue
Boise, Idaho, 83704
Fenway Community Health Ctr
Boston, Massachusetts, 02115
Bach and Godofsky
Bradenton, Florida, 34205
Med Univ of South Carolina
Charleston, South Carolina, 29425
Paul Alessi
Cherry Hill, New Jersey, 08034
Northwestern Univ Med Ctr
Chicago, Illinois, 60611
The CORE Ctr
Chicago, Illinois, 60612
Univ of Cincinnati / Holmes Hosp
Cincinnati, Ohio, 452670405
Southwest Infectious Diseases Associates
Dallas, Texas, 75246
VAMC New Jersey Healthcare System
East Orange, New Jersey, 07018
Community Health Care
Fort Lauderdale, Florida, 33306
Univ TX Galveston Med Branch
Galveston, Texas, 77555
Hampton Roads Med Specialists
Hampton, Virginia, 23666
St Mary's Hosp Family Treatment Ctr
Hoboken, New Jersey, 07030
Joseph C Gathe
Houston, Texas, 77004
Thomas Street Clinic
Houston, Texas, 77009
Indiana Univ Infectious Disease Research Clinic
Indianapolis, Indiana, 46202
Univ of Iowa
Iowa City, Iowa, 52242
Univ of Florida
Jacksonville, Florida, 32209
Kansas City AIDS Research Consortium
Kansas City, Missouri, 64111
Univ of Southern California
Los Angeles, California, 90033
University of Louisville / ID Division
Louisville, Kentucky, 40202
Univ of Miami School of Medicine
Miami, Florida, 33136
South Shore Hosp
Miami, Florida, 33139
Specialty Med Care Ctrs of South Florida Inc
Miami, Florida, 33142
Wisconsin AIDS Research Consortium
Milwaukee, Wisconsin, 53203
Hawthorne Med Associates / PAACA
New Bedford, Massachusetts, 02745
HIV Outpatient Clinics / LA State Univ Med Ctr
New Orleans, Louisiana, 70112
Bentley-Salick Medical Practice PC
New York, New York, 10003
Univ of Med & Dentistry of New Jersey
Newark, New Jersey, 07103
Highland Gen Hosp / San Francisco Gen Hosp
Oakland, California, 946021018
Univ of Nebraska Medical Ctr
Omaha, Nebraska, 681985400
Orange County Health Dept
Orlando, Florida, 32805
ViRx Inc
Palm Springs, California, 92262
Larry Bush
Palm Springs, Florida, 33461
Univ of Rochester Med Ctr
Rochester, New York, 14642
Research & Treatment at the California Pacific Med Ctr
San Francisco, California, 94114
Infectious Diseases Associates
Sarasota, Florida, 34239
Infectious Disease Research Institute
Tampa, Florida, 33614
Harbor - UCLA Med Ctr
Torrance, California, 90502
Arizona Clinical Research Ctr Inc
Tucson, Arizona, 85712
Treasure Coast Infectious Disease Consultants
Vero Beach, Florida, 32960
Julio Arroyo
West Columbia, South Carolina, 29169
Univ of Kansas School of Medicine
Wichita, Kansas, 67214
Polk County Health Dept
Winter Haven, Florida, 33881
Canada4 sites
QEII Health Science Centre
Halifax, Nova Scotia
Montreal Chest Institute
Montreal, Quebec
Sunnybrook Health Science Centre
Toronto, Ontario
Canadian HIV Trials Network
Vancouver, British Columbia
Puerto Rico2 sites
Univ of Puerto Rico School of Med
Rio Piedras, 00935
Clinical Research Puerto Rico Inc
San Juan, 009091711
Dominican Republic1 site
Immunity Care and Research Inc
Santo Domingo
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled Study of AG1549 in Combination With Viracept (Nelfinavir Mesylate) and Combivir (Zidovudine + Lamivudine) in Treatment-Naive HIV-Infected Patients
The purpose of this study is to look at the effectiveness of giving a new anti-HIV drug (AG1549) plus Viracept (nelfinavir) plus Combivir (a tablet containing zidovudine plus lamivudine) to HIV-infected patients who are not taking anti-HIV drugs.
Read the detailed description
[Note: As of 2/28/2001, due to toxicity studies and concerns for safety, sites were notified that they need to discontinue patients from the capravirine/placebo arms and continue patients with their background therapies or switch patients to new therapies, as deemed appropriate by the investigators.] Patients are randomized to receive Viracept plus Combivir plus either AG1549 or placebo. Patients remain on their assigned therapy for 48 weeks with one post-therapy follow-up visit. Blood samples are taken regularly to quantify plasma HIV-1 RNA, CD4 and CD8 counts, and peripheral blood mononuclear cells (PBMC). Physical exams, safety assessments, and other tests are also done throughout the study. A blood sample is taken at baseline (pre-dose) for a pharmacokinetics assessment. On Day 8 and at the end of Weeks 4, 8, 16, 24, 36, and 48, pharmacokinetic sampling is done prior to dosing and between 2 to 4 hours post-dose.
- Conditions
- HIV Infections
- Being tested
- Lamivudine/Zidovudine, Capravirine, Nelfinavir mesylate
- Keywords
- Drug Therapy, Combination, Zidovudine, HIV Protease Inhibitors, Lamivudine, Disease Progression, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Viral Load, Nelfinavir, Combivir
- Medical subject headings
- HIV Infections, Disease Progression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lamivudine/ZidovudineDrug
CapravirineDrug
Nelfinavir mesylateDrug
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Aug 2001 (estimated)
- Study startAug 1999
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIV InfectionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Masking
- Double blind
- Enrolment
- 350 participants
Sponsor and investigators
- Lead sponsor
- Agouron Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00004999
- Sponsor's protocol ID
- 286C
- Other IDs
- AG1549-504
- Status last verified
- Mar 2001
- First submitted
- 21 Mar 2000
- Last updated
- 24 Jun 2005
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Jun 2005. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled Study of AG1549 in Combination With Viracept (Nelfinavir Mesylate) and Combivir (Zidovudine + Lamivudine) in Treatment-Naive HIV-Infected Patients
- ClinicalTrials.gov ID
- NCT00004999
- Acronym / sponsor ID
- 286C
- Conditions
- HIV Infections
- Keywords
- Drug Therapy, Combination, Zidovudine, HIV Protease Inhibitors, Lamivudine, Disease Progression, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Viral Load
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Suspended
- Enrolment
- 350 participants
- Lead sponsor
- Agouron PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- Aug 1999
- First posted
- 31 Aug 2001 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to look at the effectiveness of giving a new anti-HIV drug (AG1549) plus Viracept (nelfinavir) plus Combivir (a tablet containing zidovudine plus lamivudine) to HIV-infected patients who are not taking anti-HIV drugs.
Detailed description
[Note: As of 2/28/2001, due to toxicity studies and concerns for safety, sites were notified that they need to discontinue patients from the capravirine/placebo arms and continue patients with their background therapies or switch patients to new therapies, as deemed appropriate by the investigators.] Patients are randomized to receive Viracept plus Combivir plus either AG1549 or placebo. Patients remain on their assigned therapy for 48 weeks with one post-therapy follow-up visit. Blood samples are taken regularly to quantify plasma HIV-1 RNA, CD4 and CD8 counts, and peripheral blood mononuclear cells (PBMC). Physical exams, safety assessments, and other tests are also done throughout the study. A blood sample is taken at baseline (pre-dose) for a pharmacokinetics assessment. On Day 8 and at the end of Weeks 4, 8, 16, 24, 36, and 48, pharmacokinetic sampling is done prior to dosing and between 2 to 4 hours post-dose.
Study design
- Primary purpose
- Treatment
- Masking
- Double blind
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Are HIV-positive.
- Are at least 18 years old.
- Have a CD4 cell count of more than 50 cells/mm3.
- Have an HIV level of more than 5000 copies/ml.
Key exclusion criteria (3 listed)
- Have ever taken any of the following anti-HIV drugs: nonnucleoside reverse transcriptase inhibitors (NNRTIs), AG1549, Viracept, zidovudine, lamivudine, or Combivir. Other anti-HIV drugs are allowed only if taken for no more than 30 days with the last dose taken more than 6 months prior to study entry.
- Have taken an experimental drug within 28 days of study entry.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lamivudine/Zidovudine | Drug | – |
| Capravirine | Drug | – |
| Nelfinavir mesylate | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jun 2005.
Related trials for HIV Infections
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Recruiting
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa
HIV, HIV Treatment
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
53 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Lamivudine/Zidovudine, Capravirine and Nelfinavir mesylate in people with HIV Infections, run by Agouron Pharmaceuticals at 53 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: paused, as of the sponsor's last update on 24 Jun 2005. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 53 sites in United States, Canada, Puerto Rico, Dominican Republic. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2005.